Literature DB >> 32914382

MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model.

Suzan M Mansour1, Hanan S El-Abhar2, Ayman A Soubh3.   

Abstract

Few reports have documented the ability of phosphodiesterase-5 inhibitors (PDE-5-Is) to ameliorate idiopathic pulmonary fibrosis (IPF) mainly by their anti-inflammatory/antioxidant capacities, without unveiling the possible molecular mechanisms involved. Because of the recent role of miR-200 family and Sonic Hedgehog (SHH) trajectory in IPF, we have studied their impact on the anti-fibrotic potential of tadalafil against bleomycin-induced pulmonary fibrosis. Animals were allocated into normal-control, bleomycin-fibrotic control, and bleomycin post-treated with tadalafil or dexamethasone, as the reference drug. On the molecular level, tadalafil has reverted the bleomycin effect on all the assessed parameters. Tadalafil upregulated the gene expression of miR-200a, but decreased the smoothened (SMO) and the transcription factors glioma-associated oncogene homolog (Gli-1, Gli-2), members of SHH pathway. Additionally, tadalafil ebbed transforming growth factor (TGF)-β, its canonical (SMAD-3/alpha smooth muscle actin [α-SMA] and Snail), and non-canonical (p-Akt/p-Forkhead box O3 (FOXO3) a) pathways. Besides, a strong negative correlation between miR-200a and the analyzed pathways was proved. The effect of tadalafil was further confirmed by the improved lung structure and the reduced Ashcroft score/collagen deposition. The results were comparable to that of dexamethasone. In conclusion, our study has highlighted the involvement of miR-200a in the anti-fibrotic effect of tadalafil with the inhibition of SHH hub and the pro-fibrotic pathways (TGF-β/ SMAD-3/α-SMA, Snail and p-AKT/p-FOXO3a). Potential anti-fibrotic effect of tadalafil. Modulation of miR200a/SHH/canonical and non-canonical TGF-β trajectories. → : stimulatory effect; ┴: inhibitory effect.

Entities:  

Keywords:  FOXO3a; Hedgehog pathway; Lung fibrosis; Tadalafil; miR200a

Year:  2020        PMID: 32914382     DOI: 10.1007/s10787-020-00748-w

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  70 in total

Review 1.  Signal transduction by the TGF-beta superfamily.

Authors:  Liliana Attisano; Jeffrey L Wrana
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

Authors:  T Ashcroft; J M Simpson; V Timbrell
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

3.  Role of Sonic Hedgehog in idiopathic pulmonary fibrosis.

Authors:  Alfredo Lozano Bolaños; Criselda Mendoza Milla; José Cisneros Lira; Remedios Ramírez; Marco Checa; Lourdes Barrera; Jorge García-Alvarez; Verónica Carbajal; Carina Becerril; Miguel Gaxiola; Annie Pardo; Moisés Selman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-09-28       Impact factor: 5.464

Review 4.  Transforming growth factor beta in tissue fibrosis.

Authors:  W A Border; N A Noble
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

5.  Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis.

Authors:  Rania R Abdelaziz; Wagdi F Elkashef; Eman Said
Journal:  Int Immunopharmacol       Date:  2016-10-18       Impact factor: 4.932

6.  The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis.

Authors:  Natacha Cigna; Elika Farrokhi Moshai; Stéphanie Brayer; Joëlle Marchal-Somme; Lidwine Wémeau-Stervinou; Aurélie Fabre; Hervé Mal; Guy Lesèche; Monique Dehoux; Paul Soler; Bruno Crestani; Arnaud A Mailleux
Journal:  Am J Pathol       Date:  2012-09-29       Impact factor: 4.307

7.  Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.

Authors:  Jürgen Behr; Steven D Nathan; Sergio Harari; Wim Wuyts; Klaus-Uwe Kirchgaessler; Monica Bengus; Frank Gilberg; Athol U Wells
Journal:  Respir Med       Date:  2018-03-16       Impact factor: 3.415

Review 8.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Benjamin D Bringardner; Christopher P Baran; Timothy D Eubank; Clay B Marsh
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats.

Authors:  Lei Chen; Tao Wang; Xun Wang; Bei-Bei Sun; Ji-Qiong Li; Dai-Shun Liu; Shang-Fu Zhang; Lin Liu; Dan Xu; Ya-Juan Chen; Fu-Qiang Wen
Journal:  Respir Res       Date:  2009-06-24

10.  FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.

Authors:  Hamza M Al-Tamari; Swati Dabral; Anja Schmall; Pouya Sarvari; Clemens Ruppert; Jihye Paik; Ronald A DePinho; Friedrich Grimminger; Oliver Eickelberg; Andreas Guenther; Werner Seeger; Rajkumar Savai; Soni S Pullamsetti
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

View more
  2 in total

1.  Artificial intelligence-assisted development of in situ forming nanoparticles for arthritis therapy via intra-articular delivery.

Authors:  Ahmed S Yacoub; Hussein O Ammar; Magdy Ibrahim; Suzan M Mansour; Nada M El Hoffy
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.

Authors:  Suzan M Mansour; Rehab N Shamma; Kawkab A Ahmed; Nirmeen A Sabry; Gamal Esmat; Azza A Mahmoud; Amr Maged
Journal:  Int Immunopharmacol       Date:  2021-07-23       Impact factor: 4.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.